All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F17%3A00067243" target="_blank" >RIV/65269705:_____/17:00067243 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/17:00097935 RIV/00209775:_____/17:N0000030

  • Result on the web

    <a href="http://dx.doi.org/10.3892/or.2017.5891" target="_blank" >http://dx.doi.org/10.3892/or.2017.5891</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3892/or.2017.5891" target="_blank" >10.3892/or.2017.5891</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

  • Original language description

    Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Oncology Reports

  • ISSN

    1021-335X

  • e-ISSN

  • Volume of the periodical

    38

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    GR - GREECE

  • Number of pages

    8

  • Pages from-to

    2535-2542

  • UT code for WoS article

    000411688200073

  • EID of the result in the Scopus database